Growth of bipolar disorder market will be curbed by generic erosion

The bipolar disorder market is expected to grow from $4.1 billion in 2020 to $4.9 billion by 2030 across the eight major markets (8MM: the USA, France, Germany, Italy, Spain, UK, Japan and Canada) at a compound annual growth rate (CAGR) of 1.7%.

According to analytics firm GlobalData, main driver of growth will be the launch of seven new pipeline products throughout the 8MM. However, despite these new product launches, only modest growth is expected in the bipolar disorder market due to generic erosion.

GlobalData’s neurology analyst Philippa Salter comments: “The bipolar disorder market is crowded and competitive, with a large number of products available for the treatment of patients, the majority of which are available as inexpensive generics. However, the new pipeline products will have significantly higher costs when compared with these generic products, which will drive market growth.”